var data={"title":"Hydrocortisone (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Hydrocortisone (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/389793?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=hydrocortisone-systemic-drug-information\" class=\"drug drug_general\">see &quot;Hydrocortisone (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=hydrocortisone-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Hydrocortisone (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116174\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>A-Hydrocort [DSC];</li>\n      <li>Cortef;</li>\n      <li>Solu-CORTEF</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116175\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cortef;</li>\n      <li>Solu-Cortef</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10820821\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Adrenal Corticosteroid</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anti-inflammatory Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiasthmatic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Corticosteroid, Systemic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Glucocorticoid</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442604\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Dose should be based on severity of disease and patient response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Bronchopulmonary dysplasia, prevention (preterm neonates with prenatal inflammatory exposure):</b> PNA &le;48 hours: IV: 1 mg/kg/day divided every 12 hours for 9 or 12 days followed by 0.5 mg/kg/day divided every 12 hours for 3 days; low-dose (ie, physiologic replacement) has been shown to be effective at improving survival without BPD in chorioamnionitis-exposed ELBW neonates (birth weight: 500 to 999 g) (Watterberg 1999; Watterberg 2004; Watterberg 2010); of note, a higher incidence of gastrointestinal perforation in the treatment arm resulted in early study closure of the largest trial (Watterberg 2004). In another trial of VLBW neonates (PNA &le;36 hours, GA &lt;30 weeks, birth weight: 500 to 1,250 g), higher dosages (ie, stress dose): 2 mg/kg/day divided every 8 hours for 2 days followed by 1.5 mg/kg/day divided every 8 hours for 2 days followed by 0.75 mg/kg/day divided every 12 hours for 6 days showed a trend in the treatment arm of decreased severity of respiratory failure, shorten length of oxygen therapy and promotion of PDA closure; this trial was closed early due to higher incidence of gastrointestinal perforation in the treatment arm versus placebo (Peltoniemi 2005). <b>Note:</b> The AAP suggests that for neonates with prenatal inflammatory exposure, low-dose hydrocortisone therapy (1 mg/kg/day) during the first 2 weeks of life may improve survival without BPD and without adverse neurodevelopmental outcomes (Watterberg 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Congenital adrenal hyperplasia:</b> Oral [tablets (crushed)]: Initial: 10 to 15 mg/m<sup>2</sup>/day in 3 divided doses; higher initial doses (20 mg/m<sup>2</sup>/day) may be required to achieve initial target hormone serum concentrations. Administer morning dose as early as possible. Due to uneven distribution of the drug in the liquid, use of oral suspension is <b>not</b> recommended [AAP 2000; Speiser (Endocrine Society) 2010]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hypoglycemia, refractory (refractory to continuous glucose infusion of &gt;12-15 mg/kg/minute):</b> Oral, IV: 5 mg/kg/day divided every 8 to 12 hours or 1 to 2 mg/kg/<b>dose</b> every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hypotension, refractory; shock:</b> IV: Limited data available; dosage regimens variable (Brierley 2009; Higgins 2010): 3 mg/kg/day divided every 8 hours for 5 days; dosing based on the largest, prospective, randomized, placebo-controlled trial of 48 hypotensive, VLBW neonates (PNA: &lt;7 days; GA: &lt;32 weeks; birth weight: &lt;1,500 g) who were also receiving dopamine at doses &ge;10 mcg/kg/minute (Ng 2006); other smaller trials have used 2 mg/kg/day divided every 12 hours for 1 to 3 days (Seri 2001) or 2 mg/kg once, followed by 2 mg/kg/day divided every 12 hours for 4 doses (Noori 2006)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10820953\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=hydrocortisone-systemic-drug-information\" class=\"drug drug_general\">see &quot;Hydrocortisone (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Adjust dose depending upon condition being treated and response of patient. The lowest possible dose should be used to control the condition; when dose reduction is possible, the dose should be reduced gradually. In life-threatening situations, parenteral doses larger than the oral dose may be needed. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adrenal insufficiency; acute (adrenal crisis):</b> Dosage regimens variable: IM, IV (preferred): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Weight-directed:</i> Limited data available: Infants, Children, and Adolescents: Initial: 2 to 3 mg/kg; maximum dose: 100 mg/dose; then for infants: 1 to 5 mg/kg/dose every 6 hours; for children and adolescents, see BSA- or age-directed dosing; may also be administered I.O. if necessary (Cameron 2012; Hegenbarth 2008; Marx 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>BSA-directed dosing:</i> Limited data available: Infants, Children, and Adolescents: Initial: 50 to 100 mg/m<sup>2</sup> once followed by 50 to 100 mg/m<sup>2</sup>/day in 4 divided doses (Ahmet 2011; Auron 2015; Hegenbarth 2008; Shulman 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Age-directed dosing (fixed dosing):</i> Limited data available (Cameron 2012; Elder 2015; Kliegman 2016): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: 10 to 25 mg once followed by 10 to 25 mg/day in divided doses every 6 hours for 24 hours then subsequent dose reductions and rate determined by patient response</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;5 years (eg, young children): 25 to 50 mg once followed by 25 to 50 mg/day in divided doses every 6 hours for 24 hours then subsequent dose reductions and rate determined by patient response</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;5 years (eg, older children): 50 to 100 mg once followed by 50 mg/day in divided doses every 6 hours for 24 hours then subsequent dose reductions and rate determined by patient response</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: 100 mg once followed by 100 mg/day in divided doses every 6 hours for 24 hours then subsequent dose reduction and rate determined by patient response</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anti-inflammatory or immunosuppressive:</b>  <b>Note:</b> Dosing range variable; individualize dose for disease state and patient response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 2.5 to 10 mg/kg/day or 75 to 300 mg/m<sup>2</sup>/day divided every 6 to 8 hours (Kliegman 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: Initial: 0.56 to 8 mg/kg/day or 20 to 240 mg/m<sup>2</sup>/day in 3 or 4 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing: Limited data available: 1 to 5 mg/kg/day or 30 to 150 mg/m<sup>2</sup>/day divided every 12 to 24 hours (Kliegman 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: Oral, IM, IV, SubQ: 15 to 240 mg every 12 hours (Kliegman 2007) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Congenital adrenal hyperplasia:</b> Infants, Children, and Adolescents: AAP Recommendations: <b>Note:</b> Administer morning dose as early as possible. Tablets may result in more reliable serum concentrations than oral liquid formulation; use of oral suspension is not recommended. Individualize dose by monitoring growth, hormone levels, and bone age; mineralocorticoid (eg, fludrocortisone) and sodium supplement may be required in salt losers (AAP 2000; AAP 2010; Endocrine Society 2010) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: Oral (tablets): 10 to 15 mg/m<sup>2</sup>/day in 3 divided doses; higher initial doses (20 mg/m<sup>2</sup>/day) may be required to achieve initial target hormone serum concentrations (AAP 2010; Endocrine Society 2010). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance dose: Oral (tablets): Usual requirement: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: 2.5 to 5 mg/<b>dose</b> 3 times/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: 5 to 10 mg/<b>dose</b> 3 times/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents (fully grown): 15 to 25 mg/day divided in 2 to 3 daily doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Physiologic replacement:</b> Infants and Children: Oral: 8 to 10 mg/m<sup>2</sup>/day divided every 8 hours; up to 12 mg/m<sup>2</sup>/day in some patients; to replicate diurnal variation, the highest doses are typically administered in the morning and midday dose with the lower dose in the evening (Ahmet 2011; Elder 2015; Gupta 2008; Maguire 2007; Shulman 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Stress dosing; supplemental:</b> Limited data available; dosage regimens variable: Infants, Children, and Adolescents: <b>Note:</b> Dosing based on the level of physiological stress related to condition, dose should be individualized based on patient and continued until resolution of stressful condition (usually 24 to 48 hours) (Shulman 2007). Typically, supplementation for emotional or minimal physiological stress conditions or prior to exercise is not necessary (Elder 2010; Endocrine Society [Speiser 2010]; Shulman 2007). Dosing is generally 2 to 3 times physiologic replacement level (Elder 2010; Shulman 2007).  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>BSA-directed dosing</i> (Ahmet 2011; Shulman 2007): Oral, IM, IV: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate stress: 20 to 50 mg/m<sup>2</sup>/day divided into 3 or 4 doses; doses on the lower end of the range (20 to 30 mg/m<sup>2</sup>/day) may be divided twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Major stress or surgery: 100 mg/m<sup>2</sup>/day in divided doses every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Planned surgery: Pre-anesthesia of 50 mg/m<sup>2</sup> IV or IM administered 30 to 60 minutes prior to surgery followed by second dose of 50 mg/m<sup>2</sup> as a continuous IV infusion or in divided doses every 6 hours for at least 24 hours   </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Age-directed for moderate stress in patients with congenital adrenal hyperplasia</i> (Endocrine Society [Speiser 2010]): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and preschool children: IV: Initial dose: 25 mg once, followed by a daily dose that is 3 to 4 times the patient's standard maintenance dose in divided doses every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">School-age children: IV: Initial dose: 50 mg once, followed by a daily dose that is 3 to 4 times the patient's standard maintenance dose in divided doses every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: IV: Initial dose: 100 mg once, followed by a daily dose that is 3 to 4 times the patient's standard maintenance dose in divided doses every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Septic shock; catecholamine-refractory with suspected/proved adrenal insufficiency:</b> Limited data available: Infants, Children, and Adolescents: IV: 50 to 100 mg/m<sup>2</sup>/day (Dellinger 2013; Marx 2014; Shulman 2007); in some cases, doses may be titrated up to 50 mg/<b>kg</b>/day if necessary for shock reversal; however, efficacy data variable with the higher doses (Brierley 2009; Menon 2012)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anti-inflammatory or immunosuppressive:</b> Oral, IM, IV: 15 to 240 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Status asthmaticus:</b> IV: 1 to 2 mg/kg/dose every 6 hours for 24 hours, then maintenance of 0.5 to 1 mg/kg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Stress dosing (surgery) in patients known to be adrenally-suppressed or on chronic systemic steroids:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Minor stress (ie, inguinal herniorrhaphy): 25 mg/day for 1 day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate stress (ie, joint replacement, cholecystectomy): 50 to 75 mg/day (25 mg every 8 to 12 hours) for 1 to 2 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Major stress (pancreatoduodenectomy, esophagogastrectomy, cardiac surgery): 100 to 150 mg/day (50 mg every 8 to 12 hours) for 2 to 3 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116380\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as sodium succinate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">A-Hydrocort: 100 mg (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as sodium succinate [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solu-CORTEF: 100 mg (1 ea); 250 mg (1 ea); 500 mg (1 ea); 1000 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as base: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cortef: 5 mg, 10 mg, 20 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg, 20 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116180\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10820961\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer with food or milk to decrease GI upset; for physiologic replacement in pediatric patients, higher doses are typically administered in the morning and midday with lower doses in the evening to replicate diurnal variation; early evening doses (18:00) may be necessary in some children (doses too close to bedtime can interfere with sleep) (Elder 2015) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Hydrocortisone sodium succinate may be administered by IM or IV routes. Dermal and/or subdermal skin depression may occur at the site of injection. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Avoid injection into deltoid muscle (high incidence of SubQ atrophy) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV bolus: Administer undiluted over at least 30 seconds; for large doses (&ge;500 mg), administer over 10 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent IV infusion: Further dilute in a compatible fluid and administer over 20 to 30 minutes (Miller 1980) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116278\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Injection: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light. Heat sensitive; do not autoclave vial. Reconstituted solutions are stable for 3 days at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light. Solutions prepared for IV infusion are stable for at least 4 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10820850\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Anti-inflammatory or immunosuppressant agent in the treatment of a variety of diseases, including those of allergic, hematologic, dermatologic, gastrointestinal, ophthalmic, neoplastic, rheumatic, autoimmune, nervous system, renal, and respiratory origin [FDA approved in pediatric patients (age not specified) and adults]; primary or secondary adrenocorticoid deficiency (drug of choice) [FDA approved in pediatric patients (age not specified) and adults]; has also been used for management of septic shock and in neonates for treatment of hypotension and prevention of bronchopulmonary dysplasia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116164\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hydrocortisone may be confused with hydrocodone, hydroxychloroquine, hydroCHLOROthiazide</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cortef may be confused with Coreg, Lortab</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HCT (occasional abbreviation for hydrocortisone) is an error-prone abbreviation (mistaken as hydroCHLOROthiazide)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solu-CORTEF may be confused with SOLU-Medrol</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116248\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atheromatous embolism, bradycardia, cardiac arrhythmia, cardiac failure (especially in susceptible patients), cardiomegaly, circulatory shock, hypertension, hypertrophic cardiomyopathy (premature infants), myocardial rupture (post-myocardial infarction), syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Arachnoiditis (intrathecal administration), depression, emotional lability, euphoria, headache, increased intracranial pressure (with pseudotumor cerebri; usually following discontinuation), insomnia, malaise, meningitis (intrathecal administration), myasthenia, neuritis, neuropathy, paraplegia (intrathecal administration), paresthesia, personality changes, psychic disorder, seizure, sensory disturbance (intrathecal administration), tingling of skin (especially in the perineal area after IV injection), vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, allergic dermatitis, alopecia, atrophic striae, burning sensation of skin (especially in the perineal area after IV injection), diaphoresis, ecchymosis, erythema (including facial), exfoliation of skin, hyperpigmentation, hypertrichosis, hypopigmentation, skin atrophy, skin rash, suppression of skin test reaction, urticaria, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Adrenal suppression, Cushing syndrome, diabetes mellitus (latent), fluid retention, glycosuria, growth suppression, hirsutism, HPA-axis suppression, hypercalcemia (associated with cancers), hyperglycemia (including increased requirements for insulin or oral hypoglycemic agents in diabetes mellitus), hypokalemia, hypokalemic alkalosis, impaired glucose tolerance, lipodystrophy, lipomatosis (epidural), menstrual disease (menstrual irregularities), moon face, negative nitrogen balance, protein catabolism, sodium retention, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distention, carbohydrate intolerance, dyspepsia, gastrointestinal disease (intrathecal administration), gastrointestinal perforation (small and large intestine, particularly in patients with inflammatory bowel disease), hiccups, increased appetite, nausea, pancreatitis, peptic ulcer (with possible perforation and hemorrhage), ulcerative esophagitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Asthenospermia, bladder dysfunction (intrathecal administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Leukocytosis, petechia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatomegaly, increased serum transaminases (usually mild elevations and reversible on discontinuation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Increased susceptibility to infection, infection, sterile abscess</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Atrophy at injection site (cutaneous and subcutaneous), postinjection flare (intra-articular use), skin edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Amyotrophy, Charcot-like arthropathy, lower extremity weakness (intrathecal administration), osteonecrosis (aseptic necrosis of femoral and humoral heads), osteoporosis, pathological fracture (long bones), rupture of tendon (particularly Achilles tendon), steroid myopathy, vertebral compression fracture</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Cataract (posterior subcapsular), exophthalmos, glaucoma, increased intraocular pressure, retinopathy (central serous chorioretinopathy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Pulmonary edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Wound healing impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylactoid reaction, blindness (periocular injection)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116223\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to hydrocortisone or any component of the formulation; systemic fungal infections; use in premature infants (formulations containing benzyl alcohol only); idiopathic thrombocytopenia purpura (IM administration only); intrathecal administration; live or live, attenuated virus vaccines (with immunosuppressive doses of corticosteroids).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for corticosteroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116244\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid reactions: Rare cases of anaphylactoid reactions have been observed in patients receiving corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermal changes: Avoid injection or leakage into the dermis; dermal and/or subdermal skin depression may occur at the site of injection. Avoid deltoid muscle injection; subcutaneous atrophy may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to killed or inactivated vaccines. Exposure to chickenpox or measles should be avoided. Corticosteroids should not be used for cerebral malaria, fungal infections, or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only fulminating or disseminated TB in conjunction with antituberculosis treatment). Latent or active amebiasis should be ruled out in any patient with recent travel to tropical climates or unexplained diarrhea prior to corticosteroid initiation. Use with extreme caution in patients with <i>Strongyloides</i> infections; hyperinfection, dissemination and fatalities have occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered (Goedert 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myopathy: Acute myopathy has been reported with high dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including euphoria, insomnia, mood swings, personality changes, severe depression, or psychotic manifestations. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with HF and/or hypertension; use has been associated with fluid retention, electrolyte disturbances, and hypertension. Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use corticosteroids with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, ulcerative colitis, abscess or other pyogenic infection) due to perforation risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Head injury: Increased mortality was observed in patients receiving high-dose IV methylprednisolone; high-dose corticosteroids should not be used for the management of head injury.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Oral steroid treatment is not recommended for the treatment of acute optic neuritis; may increase frequency of new episodes and does not affect short- or long-term visual outcomes. Use with caution in patients with ocular herpes simplex; corneal perforation may occur; do not use in active ocular herpes simplex. Consider routine eye exams in chronic users.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pheochromocytoma: Pheochromocytoma crisis has been reported with corticosteroids (may be fatal). Consider the risk of pheochromocytoma crisis prior to administering corticosteroids in patients with suspected pheochromocytoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use corticosteroids with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly with the smallest possible effective dose for the shortest duration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: May affect growth velocity; growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Diluent for injection may contain benzyl alcohol and some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol and/or benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Epidural injection: Corticosteroids are not approved for epidural injection. Serious neurologic events (eg, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, stroke), some resulting in death, have been reported with epidural injection of corticosteroids, with and without use of fluoroscopy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Stress: Patients may require higher doses when subject to stress (ie, trauma, surgery, severe infection).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26022589\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May cause osteoporosis (at any age) or inhibition of bone growth in pediatric patients. Use with caution in patients with osteoporosis. In a population-based study of children, risk of fracture was shown to be increased with &gt;4 courses of corticosteroids; underlying clinical condition may also impact bone health and osteoporotic effect of corticosteroids (Leonard 2007). In premature neonates, reports of gastrointestinal perforation in the hydrocortisone treatment arm have resulted in the closure of two large BPD clinical trials (Peltoniemi 2005; Watterberg 2004); concomitant use with indomethacin or ibuprofen may increase the risk and should be avoided in this population (Seri 2006). Increased IOP may occur especially with prolonged use; in children, increased IOP has been shown to be dose dependent and produce a greater IOP in children &lt;6 years than older children treated with ophthalmic dexamethasone (Lam 2005). Hypertrophic cardiomyopathy has been reported in premature neonates. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116271\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116272\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16001&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of Corticosteroids (Systemic). Management: No dose adjustment is needed for single 40 mg aprepitant doses. For other regimens, reduce oral dexamethasone or methylprednisolone doses by 50%, and IV methylprednisolone doses by 25%. Antiemetic regimens containing dexamethasone reflect this adjustment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Axicabtagene Ciloleucel: Corticosteroids (Systemic) may diminish the therapeutic effect of Axicabtagene Ciloleucel.  Management: Avoid use of corticosteroids as premedication before axicabtagene ciloleucel. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcitriol (Systemic): Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Hydrocortisone (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Desirudin. More specifically, corticosteroids may increase hemorrhagic risk during desirudin treatment.  Management: Discontinue treatment with systemic corticosteroids prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Corticosteroids (Systemic) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DilTIAZem: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Corticosteroids (Systemic) may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Corticosteroids (Systemic) may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mifamurtide: Corticosteroids (Systemic) may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May diminish the therapeutic effect of Corticosteroids (Systemic). MiFEPRIStone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nicorandil. Gastrointestinal perforation has been reported in association with this combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sargramostim: Corticosteroids (Systemic) may enhance the therapeutic effect of Sargramostim. Specifically, corticosteroids may enhance the myeloproliferative effects of sargramostim. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Corticosteroids (Systemic) may decrease the serum concentration of Tacrolimus (Systemic). Conversely, when discontinuing corticosteroid therapy, tacrolimus concentrations may increase. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids (Systemic).  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tisagenlecleucel: Corticosteroids (Systemic) may diminish the therapeutic effect of Tisagenlecleucel.  Management: Avoid use of corticosteroids as premedication or at any time during treatment with tisagenlecleucel, except in the case of life-threatening emergency (such as resistant cytokine release syndrome).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urea Cycle Disorder Agents: Corticosteroids (Systemic) may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Corticosteroids (Systemic) may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of Urea Cycle Disorder Agents needed to maintain these concentrations in the target range. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live). Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live).  Management: Doses equivalent to less than 2 mg/kg or 20 mg per day of prednisone administered for less than 2 weeks are not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses and longer durations should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116218\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116219\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed with corticosteroids in animal reproduction studies. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts or decreased birth weight; however, information is conflicting and may be influenced by maternal dose/indication for use (Lunghi 2010; Park-Wyllie 2000; Pradat 2003). Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When treating women with adrenal insufficiency (primary or central) during pregnancy, hydrocortisone is the preferred corticosteroid. Doses may need to be adjusted as pregnancy progresses, and stress doses may be required during active labor. Pregnant women with adrenal insufficiency should be monitored at least once each trimester (ES [Bornstein 2016]; ES [Fleseriu 2016]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications (ACOG 2008; GINA 2016). Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy; however, systemic corticosteroids should be used to control acute exacerbations or treat severe persistent asthma (ACOG 2008; GINA 2016; Namazy 2016). Women who require systemic corticosteroids for management of their asthma should be given intravenous corticosteroids, such as hydrocortisone, during labor and for 24 hours after delivery to prevent adrenal crisis (ACOG 2008).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When systemic corticosteroids are needed in pregnancy for rheumatic disorders, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimester (G&ouml;testam Skorpen 2016; Makol 2011; &Oslash;stensen 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For dermatologic disorders in pregnant women, systemic corticosteroids are generally not preferred for initial therapy; should be avoided during the first trimester; and used during the second or third trimester at the lowest effective dose (Bae 2012; Leachman 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10820962\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure; weight; serum glucose; electrolytes; growth in pediatric patients; presence of infection, bone mineral density; assess HPA axis suppression (eg, ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test). Monitor IOP with therapy &gt;6 weeks.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10820963\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Hydrocortisone (normal endogenous morning levels): 4 to 30 mcg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116300\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Short-acting corticosteroid with minimal sodium-retaining potential; decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116303\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: IV: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral:  96% &plusmn; 20% (Czock 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: IV: 27 &plusmn; 7 L (Czock 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: IV: 92% &plusmn; 2% (Czock 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV: 2 &plusmn; 0.3 hours; Oral: 1.8 &plusmn; 0.5 hours (Czock 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Oral: 1.2 &plusmn; 0.4 hours (Czock 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (Czock 2005)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10821086\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Cortef oral suspension was reformulated in July 1998; the suspending agent was changed from tragacanth to xanthan gum; this suspension was found <b>not</b> to be bioequivalent to hydrocortisone tablets in the treatment of children with congenital adrenal hyperplasia; children required higher doses of the suspension (19.6 mg/m<sup>2</sup>/day) compared to the tablets (15.2 mg/m<sup>2</sup>/day); based on these findings, Cortef suspension was voluntarily recalled from the market on July 18, 2000 (Merke 2001).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In premature neonates, the use of high-dose dexamethasone (approximately &gt;0.5 mg/kg/day) for the prevention or treatment of BPD has been associated with adverse neurodevelopmental outcomes, including higher rates of cerebral palsy without additional clinical benefit over lower doses; current data does not support use of high doses. Data specific to hydrocortisone use in this population has shown that use &lt;7 days of therapy does not appear to be associated with adverse neurodevelopmental outcomes (Needelman 2010).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Hydrocortisone has been studied in children with cystic fibrosis and an ongoing lower respiratory tract infection using 2.5 mg/kg/<b>dose</b> every 6 hours for 10 days in addition to standard therapies. A double-blind, placebo- controlled trial of 22 infants and children (age: &lt;18 months; mean: 8.8 to 9.5 months) showed no significant difference in pulmonary function on day 10 of therapy between treatment and placebo groups; however, at 1 to 2 months after discharge, follow-up testing showed significant, sustained improvement of pulmonary function in the hydrocortisone group compared to placebo (Tepper 1997). Hydrocortisone is not recommended for routine use in current cystic fibrosis guidelines (Flume 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11585944\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>2 mg/mL Oral Suspension (ASHP Standard Concentration)</b> (ASHP 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 2 mg/mL oral suspension may be made with 10 mg tablets and a 1:1 mixture of Ora-Sweet and Ora-Plus. Crush ten 10 mg hydrocortisone tablets in a mortar and reduce to a fine powder. Add a small amount of vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 50 mL; transfer to a calibrated amber bottle, rinse mortar with vehicle, and add sufficient quantity of vehicle to make 50 mL. Label &ldquo;shake well.&rdquo; Stable under refrigeration or at room temperature for 90 days.</p>\n    <div class=\"reference\">Chong G, Decarie D, Ensom MHH. Stability of hydrocortisone in extemporaneously compounded suspension. <i>J Inform Pharmacother.</i> 2003;13:100-110.</div>\r\n\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>2.5 mg/mL Oral Suspension</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 2.5 mg/mL oral suspension may be made with either tablets or powder and a vehicle containing sodium carboxymethylcellulose (1 g), syrup BP (10 mL), hydroxybenzoate 0.1% preservatives (0.1 g), polysorbate 80 (0.5 mL), citric acid (0.6 g), and water. To make the vehicle, dissolve the hydroxybenzoate, citric acid, and syrup BP in hot water. Cool solution and add the carboxymethylcellulose; leave overnight. Crush twelve-and-one-half 20 mg hydrocortisone tablets (or use 250 mg of powder) in a mortar and reduce to a fine powder while adding polysorbate 80. Add small portions of vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 100 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add sufficient quantity of vehicle to make 100 mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate.&rdquo; Stable for 90 days.</p>\n    <div class=\"reference\">Fawcett JP, Boulton DW, Jiang R, et al. Stability of hydrocortisone oral Suspensions prepared from tablets and powder. <i>Ann Pharmacother.</i> 1995;29(10):987-990.<span class=\"pubmed-id\">8845559</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116382\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Solu-CORTEF Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $16.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (1): $29.81</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $59.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (1): $119.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Cortef Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (50): $59.41</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $200.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $380.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Hydrocortisone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (50): $16.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $57.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $108.70</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961979\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actocortina (ES);</li>\n      <li>Aftasone (ES);</li>\n      <li>Arvisone (IN);</li>\n      <li>Biocort (PH);</li>\n      <li>Cipcorlin (IN);</li>\n      <li>Clovisone (PH);</li>\n      <li>Colifoam (AE, AT, AU, DE, DK, FI, GB, GR, IE, IT, MT, NZ, PT, SE);</li>\n      <li>Colofoam (FR);</li>\n      <li>Corhydron (PL);</li>\n      <li>Coripen (UY);</li>\n      <li>Cort-S (ET, IN, LK);</li>\n      <li>Cortaject (ZA);</li>\n      <li>Cortef (BB, BD, HR, HU, TH);</li>\n      <li>Cortifoam (IL);</li>\n      <li>Cortin (PH);</li>\n      <li>Cortis-100 (PH);</li>\n      <li>Cortisol (PK, UY);</li>\n      <li>Cortisol L.C.H. (CL);</li>\n      <li>Cortisona (BR);</li>\n      <li>Covocort (ZA);</li>\n      <li>Dhartisone-100 (ID);</li>\n      <li>Drosodin (MX);</li>\n      <li>Efcorlin (IN);</li>\n      <li>Entofoam (IN);</li>\n      <li>Fartison (ID);</li>\n      <li>Flebocortid (IT, MX);</li>\n      <li>Flemex (MX);</li>\n      <li>Fridalit (AR);</li>\n      <li>Harond (KR);</li>\n      <li>Hidrocort (VE);</li>\n      <li>Hidrocortif (EC);</li>\n      <li>Hidrotisona (AR);</li>\n      <li>Hison (BD);</li>\n      <li>Hycort (BD, PH);</li>\n      <li>Hycortil (PH);</li>\n      <li>Hydrocort (IL);</li>\n      <li>Hydrocortistab (CY);</li>\n      <li>Hydrosone (SA);</li>\n      <li>Hydrotopic (PH);</li>\n      <li>Hyson (TW);</li>\n      <li>Hysone (AU, KR);</li>\n      <li>Kortef (UA);</li>\n      <li>Lyo-Cortin (GR);</li>\n      <li>M-Cort (IN);</li>\n      <li>Nositrol (MX);</li>\n      <li>Oralsone (AR);</li>\n      <li>Plenadren (CZ, DE, DK, EE, ES, GB, HR, HU, IS, LT, LV, MT, NL, NO, PL, PT, SE, SK);</li>\n      <li>Primacor (LK);</li>\n      <li>Primacort (PE);</li>\n      <li>Rapicort (PT);</li>\n      <li>Rapison (JP, KR);</li>\n      <li>Rolak (GR);</li>\n      <li>Samcort (LK);</li>\n      <li>Saxizon (JP);</li>\n      <li>Solhidrol (MX);</li>\n      <li>Solu Cortef (AE, BD, BE, BH, BR, CH, CL, CO, CY, DK, EC, EE, EG, ET, FI, GB, GR, HK, HN, HR, HU, IE, IS, IT, JO, KR, KW, LB, LU, LV, MY, NL, NO, PE, PH, PK, PT, QA, RU, SA, SE, SG, TH, TR, TW, UA, ZA, ZW);</li>\n      <li>Solu-Cortef (AU, BB, CN, JP, MT, NZ, VE, VN);</li>\n      <li>Solu-Tisone (TW);</li>\n      <li>Stericort (PH);</li>\n      <li>Unicort (BD);</li>\n      <li>Zonac (PY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics, &quot;ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 90, February 2008: Asthma in Pregnancy,&quot; <i>Obstet Gynecol</i>, 2008, 111(2 Pt 1):457-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/18238988/pubmed\" target=\"_blank\" id=\"18238988\">18238988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahmet A, Kim H, and Spier S, &quot;Adrenal Suppression: A Practical Guide to the Screening and Management of this Under-Recognized Complication of Inhaled Corticosteroid Therapy,&quot; <i>Allergy Asthma Clin Immunol</i>, 2011, 7:13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/21867553/pubmed\" target=\"_blank\" id=\"21867553\">21867553</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, &quot;Statement of Endorsement-Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency,&quot; Pediatrics, 2010, 126(5):1051. Available at http://pediatrics.aappublications.org/cgi/content/extract/126/5/1051. Accessed May 10, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, Section on Endocrinology and Committee on Genetics, &quot;Technical Report: Congenital Adrenal Hyperplasia,&quot; <i>Pediatrics</i>, 2000, 106(6):1511-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/11099616 /pubmed\" target=\"_blank\" id=\"11099616 \">11099616 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Annane D, S&eacute;bille V, Charpentier C, et al, &quot;Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock,&quot; <i>JAMA</i>, 2002, 288(7):862-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/12186604/pubmed\" target=\"_blank\" id=\"12186604\">12186604</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arlt W and Allolio B, &quot;Adrenal Insufficiency,&quot; <i>Lancet</i>, 2003, 361(9372):1881-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/12788587/pubmed\" target=\"_blank\" id=\"12788587\">12788587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Auron M, Raissouni N. Adrenal insufficiency. <i>Pediatr Rev</i>. 2015;36(3):92-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/25733761 /pubmed\" target=\"_blank\" id=\"25733761 \">25733761 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bae YS, Van Voorhees AS, Hsu S, et al, &quot;Review of Treatment Options For Psoriasis in Pregnant or Lactating Women: From the Medical Board of the National Psoriasis Foundation,&quot; <i>J Am Acad Dermatol</i>, 2012, 67(3):459-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/22018758/pubmed\" target=\"_blank\" id=\"22018758\">22018758</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(2):364-389. doi: 10.1210/jc.2015-1710.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/26760044/pubmed\" target=\"_blank\" id=\"26760044\">26760044</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brierley J, Carcillo JA, Choong K, et al, &quot;Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update From the American College of Critical Care Medicine,&quot; <i>Crit Care Med</i>, 2009, 37(2):666-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/19325359/pubmed\" target=\"_blank\" id=\"19325359\">19325359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/24528912/pubmed\" target=\"_blank\" id=\"24528912\">24528912</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cameron P, Jelinek G, Everitt I, Browne G, Raftos J, eds. <i>Textbook of Paediatric Emergency Medicine</i>. Toronto: Elsevier; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carcillo JA and Fields AI, &quot;Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Patients in Septic Shock,&quot; <i>Crit Care Med</i>, 2002, 30(6):1365-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/12072696/pubmed\" target=\"_blank\" id=\"12072696\">12072696</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cowett RM and Loughead JL, &quot;Neonatal Glucose Metabolism: Differential Diagnoses, Evaluation, and Treatment of Hypoglycemia,&quot; <i>Neonatal Netw</i>, 2002, 21(4):9-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/12078323/pubmed\" target=\"_blank\" id=\"12078323\">12078323</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dellinger RP, Levy MM, Carlet JM, et al, &quot;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&quot; <i>Intensive Care Med</i>, 2008, 34(1):17-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/18058085/pubmed\" target=\"_blank\" id=\"18058085\">18058085</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. <i>Crit Care Med</i>. 2013;41(2):580-637.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/23353941/pubmed\" target=\"_blank\" id=\"23353941\">23353941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elder CJ, Dimitri P. Hydrocortisone for adrenal insufficiency. <i>Arch Dis Child Educ Pract Ed</i>. 2015;100(5):272-276.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/25561746 /pubmed\" target=\"_blank\" id=\"25561746 \">25561746 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(11):3888-3921. doi: 10.1210/jc.2016-2118.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/27736313/pubmed\" target=\"_blank\" id=\"27736313\">27736313</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flume PA, Mogayzel PJ Jr, Robinson KA, et al, &quot;Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations,&quot; <i>Am J Respir Crit Care Med</i>, 2009, 180(9):802-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/19729669/pubmed\" target=\"_blank\" id=\"19729669\">19729669</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). GINA report, Global Strategy for Asthma Management and Prevention. Available at http://www.ginasthma.org. Updated 2016. Accessed June 8, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    G&ouml;testam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. <i>Ann Rheum Dis</i>. 2016;75(5):795-810.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/26888948/pubmed\" target=\"_blank\" id=\"26888948\">26888948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta P and Bhatia V, &quot;Corticosteroid Physiology and Principles of Therapy,&quot; <i>Indian J Pediatr</i>, 2008, 75(10):1039-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/19023528/pubmed\" target=\"_blank\" id=\"19023528\">19023528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halamek LP and Stevenson DK, &quot;Neonatal Hypoglycemia, Part II: Pathophysiology and Therapy,&quot; <i>Clin Pediatr (Phila)</i>, 1998, 37(1):11-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/9475694/pubmed\" target=\"_blank\" id=\"9475694\">9475694</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Han YY, Carcillo JA, Dragotta MA, et al, &quot;Early Reversal of Pediatric-Neonatal Septic Shock by Community Physicians is Associated With Improved Outcome,&quot; <i>Pediatrics</i>, 2003, 112(4):793-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/14523168/pubmed\" target=\"_blank\" id=\"14523168\">14523168</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA, American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008;121(2):433-443.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/18245435 /pubmed\" target=\"_blank\" id=\"18245435 \">18245435 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Higgins S, Friedlich P, and Seri I, &quot;Hydrocortisone for Hypotension and Vasopressor Dependence in Preterm Neonates: A Meta-Analysis,&quot; <i>J Perinatol</i>, 2010, 30(6):373-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/19693023/pubmed\" target=\"_blank\" id=\"19693023\">19693023</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hydrocortisone tablets [prescribing information]. Columbus, OH: American Health Packaging; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jain A, Aggarwal R, Jeevasanker M, et al, &quot;Hypoglycemia in the Newborn,&quot; <i>Indian J Pediatr</i>, 2008, 75(1):63-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/18245938/pubmed\" target=\"_blank\" id=\"18245938\">18245938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam DS, Fan DS, Ng JS, et al, &quot;Ocular Hypertensive and Anti-Inflammatory Responses to Different Dosages of Topical Dexamethasone in Children: A Randomized Trial,&quot; <i>Clin Experiment Ophthalmol</i>, 2005, 33(3):252-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/15932528/pubmed\" target=\"_blank\" id=\"15932528\">15932528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leachman SA and Reed BR, &quot;The Use of Dermatologic Drugs in Pregnancy and Lactation,&quot; <i>Dermatol Clin</i>, 2006, 24(2):167-97, vi.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/16677965/pubmed\" target=\"_blank\" id=\"16677965\">16677965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leonard MB, &quot;Glucocorticoid-Induced Osteoporosis in Children: Impact of the Underlying Disease,&quot; <i>Pediatrics</i>, 2007, 119 Suppl 2:S166-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/17332238/pubmed\" target=\"_blank\" id=\"17332238\">17332238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lunghi L, Pavan B, Biondi C, et al, &quot;Use of Glucocorticoids in Pregnancy,&quot;<i> Curr Pharm Des</i>, 2010, 16(32):3616-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/20977425/pubmed\" target=\"_blank\" id=\"20977425\">20977425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maguire AM, Ambler GR, Moore B, et al, &quot;Prolonged Hypocortisolemia in Hydrocortisone Replacement Regimens in Adrenocorticotrophic Hormone Deficiency,&quot; <i>Pediatrics</i>, 2007, 120(1):164-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/17576782/pubmed\" target=\"_blank\" id=\"17576782\">17576782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Makol A, Wright K, and Amin S, &quot;Rheumatoid Arthritis and Pregnancy: Safety Considerations in Pharmacological Management,&quot; <i>Drugs</i>, 2011, 71(15):1973-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/21985166/pubmed\" target=\"_blank\" id=\"21985166\">21985166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marik PE, Pastores SM, Annane D, et al, &quot;Recommendations for the Diagnosis and Management of Corticosteroid Insufficiency in Critically Ill Adult Patients: Consensus Statements From an International Task Force by the American College of Critical Care Medicine,&quot; <i>Crit Care Med</i>, 2008, 36(6):1937-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/18496365/pubmed\" target=\"_blank\" id=\"18496365\">18496365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marx, JA, ed. <i>Rosen's Emergency Medicine: Concepts and Clinical Practice</i>. 8th ed. Elsevier, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menon, K. Use of hydrocortisone for refractory shock in children. <i>Crit Care Med</i>. 2013;41(10):e294-295.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/24060796 /pubmed\" target=\"_blank\" id=\"24060796 \">24060796 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Merke DP, Cho D, Calis KA, et al, &quot;Hydrocortisone Suspension and Hydrocortisone Tablets are not Bioequivalent in the Treatment of Children With Congenital Adrenal Hyperplasia,&quot; <i>J Clin Endocrinol Metab</i>, 2001, 86(1):441-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/11232038/pubmed\" target=\"_blank\" id=\"11232038\">11232038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller JJ 3rd. Prolonged use of large intravenous steroid pulses in the rheumatic diseases of children. <i>Pediatrics</i>. 1980;65(5):989-994.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/6966050 /pubmed\" target=\"_blank\" id=\"6966050 \">6966050 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Namazy J, Schatz M. The treatment of allergic respiratory disease during pregnancy. <i>J Investig Allergol Clin Immunol</i>. 2016;26(1):1-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/27012010/pubmed\" target=\"_blank\" id=\"27012010\">27012010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Needelman H, Hoskoppal A, Roberts H, et al, &quot;The Effect of Hydrocortisone on Neurodevelopmental Outcome in Premature Infants Less Than 29 Weeks' Gestation,&quot; <i>J Child Neurol</i>, 2010, 25(4):448-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/20139411/pubmed\" target=\"_blank\" id=\"20139411\">20139411</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ng PC, Lee CH, Bnur FL, et al, &quot;A Double-Blind, Randomized, Controlled Study of a 'Stress Dose' of Hydrocortisone for Rescue Treatment of Refractory Hypotension in Preterm Infants,&quot; <i>Pediatrics</i>, 2006, 117(2):367-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/16452355/pubmed\" target=\"_blank\" id=\"16452355\">16452355</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Noori S, Friedlich P, Wong P, et al, &quot;Hemodynamic Changes After Low-Dosage Hydrocortisone Administration in Vasopressor-Treated Preterm and Term Neonates,&quot; <i>Pediatrics</i>, 2006, 118(4):1456-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/17015536/pubmed\" target=\"_blank\" id=\"17015536\">17015536</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &Oslash;stensen M and Forger F, &quot;Management of RA Medications in Pregnant Patients,&quot; <i>Nat Rev Rheumatol</i>, 2009, 5(7):382-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/19506586/pubmed\" target=\"_blank\" id=\"19506586\">19506586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ost L, Wettrell G, Bjorkhem I, et al, &quot;Prednisolone Excretion in Human Milk,&quot; <i>J Pediatr</i>, 1985, 106(6):1008-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/3998938/pubmed\" target=\"_blank\" id=\"3998938\">3998938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park-Wyllie L, Mazzotta P, Pastuszak A, et al, &quot;Birth Defects After Maternal Exposure to Corticosteroids: Prospective Cohort Study and Meta-Analysis of Epidemiological Studies,&quot; <i>Teratology</i>, 2000, 62(6):385-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/11091360/pubmed\" target=\"_blank\" id=\"11091360\">11091360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peltoniemi O, Kari MA, Heinonen K, et al, &quot;Pretreatment Cortisol Values May Predict Responses to Hydrocortisone Administration for the Prevention of Bronchopulmonary Dysplasia in High-Risk Infants,&quot; <i>J Pediatr</i>, 2005, 146(5):632-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/15870666/pubmed\" target=\"_blank\" id=\"15870666\">15870666</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pradat P, Robert-Gnansia E, Di Tanna GL, et al, &ldquo;First Trimester Exposure to Corticosteroids and Oral Clefts,&rdquo; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(12):968-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/14745915/pubmed\" target=\"_blank\" id=\"14745915\">14745915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seri I, &quot;Hydrocortisone and Vasopressor-Resistant Shock in Preterm Neonates,&quot; <i>Pediatrics</i>, 2006, 117(2):516-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/16452371/pubmed\" target=\"_blank\" id=\"16452371\">16452371</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seri I, Tan R, and Evans J, &quot;Cardiovascular Effects of Hydrocortisone in Preterm Infants With Pressor-Resistant Hypotension,&quot; <i>Pediatrics</i>, 2001, 107(5):1070-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/11331688/pubmed\" target=\"_blank\" id=\"11331688\">11331688</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman DI, Palmert MR, Kemp SF, Lawson Wilkins Drug and Therapeutics Committee. Adrenal insufficiency: still a cause of morbidity and death in childhood. <i>Pediatrics</i>. 2007;119(2):e484-494.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/17242136/pubmed\" target=\"_blank\" id=\"17242136\">17242136</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solu-Cortef (hydrocortisone systemic) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Co; May 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Speiser PW, Azziz R, Baskin LS, et al, &quot;Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline,&quot; <i>J Clin Endocrinol Metab</i>, 2010, 95(9):4133-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/20823466/pubmed\" target=\"_blank\" id=\"20823466\">20823466</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tepper RS, Eigen H, Stevens J, et al, &quot;Lower Respiratory Illness in Infants and Young Children With Cystic Fibrosis: Evaluation of Treatment With Intravenous Hydrocortisone,&quot; <i>Pediatr Pulmonol</i>, 1997, 24(1):48-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/9261853/pubmed\" target=\"_blank\" id=\"9261853\">9261853</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watterberg KL and American Academy of Pediatrics Committee on Fetus and Newborn, &quot;Policy Statement--Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia,&quot; <i>Pediatrics</i>, 2010, 126(4):800-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/20819899/pubmed\" target=\"_blank\" id=\"20819899\">20819899</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watterberg KL, Gerdes JS, Cole CH, et al, &quot;Prophylaxis of Early Adrenal Insufficiency to Prevent Bronchopulmonary Dysplasia: A Multicenter Trial,&quot; <i>Pediatrics</i>, 2004, 114(6):1649-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/15574629/pubmed\" target=\"_blank\" id=\"15574629\">15574629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watterberg KL, Gerdes JS, Gifford KL, et al, &quot;Prophylaxis Against Early Adrenal Insufficiency to Prevent Chronic Lung Disease in Premature Infants,&quot; <i>Pediatrics</i>, 1999, 104(6):1258-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/10585975/pubmed\" target=\"_blank\" id=\"10585975\">10585975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16001 Version 186.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8116174\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8116175\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10820821\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442604\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10820953\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8116380\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F8116180\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10820961\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F8116278\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10820850\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8116164\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8116248\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8116223\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8116244\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26022589\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8116271\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8116272\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8116218\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8116219\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10820962\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F10820963\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8116300\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F8116303\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F10821086\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F11585944\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8116382\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961979\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16001|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=hydrocortisone-systemic-drug-information\" class=\"drug drug_general\">Hydrocortisone (systemic): Drug information</a></li><li><a href=\"topic.htm?path=hydrocortisone-systemic-patient-drug-information\" class=\"drug drug_patient\">Hydrocortisone (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}